<p>|Recommendation|Level of evidence (evidence [refs.] reviewed)†|
|---|---|
|In adult patients with active PsA despite treatment with an OSM,| |
|1. Switch to a TNFi biologic over a different OSM (PICO 23)|Moderate (62–66, 69–86)|
|Conditional recommendation based on moderate-quality evidence; may consider switching to a different OSM if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, if the patient prefers an oral versus parenteral therapy, or in patients without evidence of severe PsA‡ or severe psoriasis.§| |
|2. Switch to a TNFi biologic over an IL-17i biologic (PICO 17)|Moderate (62–66, 72–78, 87–97)|